Anti-IL-5 (Reslizumab), Humanized Antibody

Datasheet
Specifications
Clonality: Monoclonal
Host: Recombinant
Reactivity: Human
Additional Information
Synonyms: CEP-38072, DCP 835, DCP-835, SCH-55700, SCH55700, EDF, TRF, IL5
UniProt ID: DB06602

Immunogen

Human IL-5

Background

The research-grade biosimilar is a humanized IgG4 kappa monoclonal antibody that targets IL-5. IL-5 is a proinflammatory cytokine that mediates recruitment, activation, growth, differentiation, and survival of eosinophils. Increased production of eosinophils is associated with allergic and non-allergic forms of asthma. The antibody specifically binds to the ERRR region (between amino acids 89-92) of the IL-5, which is necessary for the interaction with the IL-5 receptor located on the eosinophil cell surface. This results in inhibition of IL-5 mediated signaling, prevents maturation of the eosinophils, and eosinophil-mediated inflammation. The original drug received approval from the FDA as an add-on treatment for patients suffering from severe asthma with an eosinophilic phenotype.

  • Catalog Number
    A2167-100-BV
  • Supplier
    BioVision
  • Size
  • Shipping
    Blue Ice
  • Price
  • 555,00 €
Add to Cart
you need any help?

Please contact:

Dr. Monika Haas

Tel. +49 (0) 6221 71415 16 info@biocat.com